AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03795272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00420043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Study NCT00420043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Study NCT02176252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Study NCT02176252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03334786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT
Description: Oral Disintegrating Tablet
Study NCT01030926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Study NCT01030926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: 0.4 U/kg body weight injected subcutaneously (under the skin), single dose
Study NCT02565667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KOL
Description: KOL staple was used for rectal anastomosis
Study NCT02565667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional staple
Description: traditional staple was used for rectal anastomosis
Study NCT03144934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
Study NCT03144934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo of GX-I7 described above.
Study NCT01034670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual axis endoscopic microscope
Description: This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
Study NCT01034670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wide field fluorescence system
Description: This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
Study NCT01034670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellVizio
Description: Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
Study NCT01034670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescent Peptide
Description: microdosing; Topical through the endoscope
Study NCT01034670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein
Description: 100 mcg topical
Study NCT01034670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: 100 mcg topical
Study NCT01627288 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost radiation
Description: Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
Study NCT00711477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/bupropion SR 360 mg/day
Study NCT00711477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00711477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scan
Description: fMRI to assess the effects of the drug/placebo on areas of the brain
Study NCT00711477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fMRI scan
Description: fMRI to assess the effects of the drug/placebo on areas of the brain
Study NCT03849118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab
Description: Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
Study NCT04765228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
Study NCT04765228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib
Study NCT01456897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: orally administered once daily
Study NCT00493051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAM501
Description: Ad5PDGF-B formulated in a collagen gel
Study NCT00493051 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Collagen gel
Study NCT00493051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: moist dressing changes daily
Study NCT02657603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injected through the new Catheter (LAX)
Study NCT02657603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injected through the new Catheter (SAX)
Study NCT02657603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAX insertion of catheter
Description: ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
Study NCT02657603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAX insertion of catheter
Description: ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
Study NCT02377739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: patients will undergo a nocturnal non-invasive ventilation
Study NCT01339520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scorecard
Description: Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
Study NCT01339520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard of care for diabetes subjects
Study NCT04535453 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.
Study NCT04535453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.
Study NCT02980913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo eye drops and Thealoz Duo gel
Description: Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
Study NCT02980913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo gel
Description: Thealoz Duo gel during the day and at night for 7 days
Study NCT01911962 — intervention group
Intervention type: PROCEDURE
Intervention: transvaginal laparoscopic surgery
Study NCT04279613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0361-0041
Description: Recombinant supercoiled plasmid encoding four human proteins: (pre-proinsulin (PPI), transforming growth factor β1 (TGF-β1), interleukin-10 (IL-10), and interleukin-2 (IL-2) is administered s.c. via syringe and needle.
Study NCT04279613 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02929407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 204205
Description: In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial.
Study NCT02929407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
Study NCT03418961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Given PO
Study NCT03418961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02398591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 53718678
Description: JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
Study NCT03418961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03418961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT00982059 — intervention group
Intervention type: OTHER
Intervention: Colonoscopic examination
Description: All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
Study NCT00850421 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum Toxin Type A
Description: 100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
Study NCT00280748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed disodium
Description: 500 mg/m2 once every 21 days up to 126 days
Study NCT00280748 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
Study NCT04978103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: A dietary supplement (Powdered exudates of Acacia Senegal (Gum Arabic E-414))
Study NCT03794830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manipulation group (MG)
Description: Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
Study NCT03794830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electrotheraphy group (EG)
Description: Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
Study NCT00152269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 12 months
Study NCT00152269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25mg Tablet, oral Daily for 12 months
Study NCT00152269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Tablet, oral Daily for 12 months
Study NCT04006275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonovue and Sonazoid
Description: Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio.
Study NCT04006275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid and Sonovue
Description: Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio.
Study NCT02036853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (\~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (\~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established.
Study NCT01629446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine hydrochloride
Description: Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
Study NCT03497351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
Study NCT03497351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urapidil
Description: The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
Study NCT01563133 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-FNA
Description: Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
Study NCT01563133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nCLE
Description: needle-based Confocal Laser Endomicroscopy
Study NCT04423341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol Oral Solution [Epidiolex]
Description: 100 mg BID for three months Placebo oral solution for three months
Study NCT03415711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3®
Description: VSL#3® 450 billion sachets
Study NCT03415711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine 2.4 g/day in once daily administration.
Study NCT03415711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Mesalamine 2.4 g/day in once daily administration.
Study NCT03415711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: sachets with maltose, cornstarch and dioxide
Study NCT04023734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders, habit-based strategies and/or involvement of family member
Description: Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit.
Study NCT04023734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling to increase knowledge
Description: The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
Study NCT04023734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling to increase motivation
Description: The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
Study NCT04023734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explore/address other drug related problems
Description: The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
Study NCT04023734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care based on the Indonesian guideline
Description: Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
Study NCT01638182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 27 participants received for three months 1 placebo capsule per day
Study NCT01638182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1-capsules
Description: 27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
Study NCT01638182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2-capsules
Description: 27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
Study NCT02246465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Study NCT04609644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Tools for Asthma Self-Management
Description: Please see description of active study arm.
Study NCT02762370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single 5 mL IA injection
Study NCT02762370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40 mg
Description: Single 1 mL IA injection
Study NCT03572608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
Study NCT05589558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)
Description: TRUS-guided biopsy - extensive number of biopsies taken transrectally involving peripheral and transitional zones (8-12 cores); cognitive biopsy - targeted biopsy with MRI information and TRUS guidance but without fusion technology (2-4 cores); fusion biopsy - targeted biopsy with MRI information using MRI/TRUS fusion technology (2-4 core); transperineal template mapping biopsy - systematic transperineal TRUS-guided biopsy with special template use to aid accurate placement of biopsy needles (more than 20 cores).
Study NCT00246740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periostat
Description: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.